IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

Journal name:
Nature
Volume:
483,
Pages:
479–483
Date published:
DOI:
doi:10.1038/nature10866
Received
Accepted
Published online
Corrected online

Both genome-wide genetic and epigenetic alterations are fundamentally important for the development of cancers, but the interdependence of these aberrations is poorly understood. Glioblastomas and other cancers with the CpG island methylator phenotype (CIMP) constitute a subset of tumours with extensive epigenomic aberrations and a distinct biology1, 2, 3. Glioma CIMP (G-CIMP) is a powerful determinant of tumour pathogenicity, but the molecular basis of G-CIMP remains unresolved. Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by remodelling the methylome. This remodelling results in reorganization of the methylome and transcriptome. Examination of the epigenome of a large set of intermediate-grade gliomas demonstrates a distinct G-CIMP phenotype that is highly dependent on the presence of IDH mutation. Introduction of mutant IDH1 into primary human astrocytes alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas. Furthermore, the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural glioblastomas but not other glioblastomas, and are predictive of improved survival. Our findings demonstrate that IDH mutation is the molecular basis of CIMP in gliomas, provide a framework for understanding oncogenesis in these gliomas, and highlight the interplay between genomic and epigenomic changes in human cancers.

At a glance

Figures

  1. Introduction of mutant IDH1 into human astrocytes remodels the methylome.
    Figure 1: Introduction of mutant IDH1 into human astrocytes remodels the methylome.

    a, Expression of wild-type and mutant IDH1 (R132H) in immortalized human astrocytes (passage 5). b, Overexpression of mutant IDH1 but not wild-type (WT) IDH1 in human astrocytes leads to production of 2-HG8. Error bars show 1 standard deviation (s.d.) (n = 2). c, Self-organizing map (SOM) analysis of methylome data for wild-type IDH1-expressing, mutant IDH1-expressing (R132H), and parental (control) cell lines shows changes in the methylome in mutant IDH1-expressing and wild-type IDH1-expressing astrocytes, compared to parental cells. Mosaic patterns are pseudo-coloured SOMs from different time points (Pindicatespassage number). Tile colours indicate methylation level of centroids. d, Hierarchical clustering showing divergence of the methylome of IDH1-expressing astrocytes from that of parental astrocytes. MUT,mutant; PAR,parental. e, Heatmap showing the 10,678 most significant differentially methylated probes (ANOVA) in IDH1 mutant astrocytes and parental astrocytes (passages 2 and 40). Colour scale indicates β values. f, Kinetics of differential methylation in mutant and wild-type-expressing astrocytes. Error bars indicate inter-quartile range (n = 2).

  2. Global epigenetic analysis of LGGs reveals dependence of G-CIMP on IDH mutation.
    Figure 2: Global epigenetic analysis of LGGs reveals dependence of G-CIMP on IDH mutation.

    a, Identification of G-CIMP by K-means consensus clustering of LGG samples. Unsupervised clustering was performed with the most variant probes (9,711 probes, top 2%). Tumours are listed in the same order along the x and y axes. G-CIMP status is indicated by the black and white bars. Consensus index values range from 0 to 1, with 0 being dissimilar (white) and 1 being similar (red). K = 2 is identified by the Lorenz curve. b, Two-dimensional (2D) hierarchical clustering of the same probes as in a identified the same two clusters. Each row represents a tumour and each column represents a probe. CIMP and IDH mutation status are indicated by the colour code. The level of DNA methylation (β value) for each probe is represented by colour scale (red,methylated; blue,non-methylated). Only cancer-specific events were used27. c, Kaplan–Meier survival curve of Memorial Sloan-Kettering Cancer Center (MSKCC) patients (n = 72) with LGG (grade II and III). d, Receiver operating characteristic (ROC) curve comparing the sensitivity and specificity of G-CIMP status compared with MGMT methylation or MGMT expression status, in LGGs. Areas under the curve are noted in the inset. G-CIMP, MGMT methylation and MGMT expression were determined as described in Methods.

  3. IDH1 mutation directly generates the methylation patterns present in G-CIMP tumours.
    Figure 3: IDH1 mutation directly generates the methylation patterns present in G-CIMP tumours.

    a, The methylomes and transcriptomes of LGGs are distinct. PCA plot of LGG tumours for all methylation probes (left) and expression probes (right) (n = 52). PC, principal component. b, Starburst plot (left) for comparison of DNA methylation and gene expression. The log10 (FDR-corrected P value) is plotted for β value for DNA methylation (x axis) and gene expression (y axis) for each gene. Black dotted lineshowsthe FDR-adjusted P value of 0.05. Red points indicatedownregulated and hypermethylated genes in G-CIMP+ LGGs versus G-CIMP− LGGs. Blue pointsshowhypomethylated and upregulated genes. Volcano (right) plot of all CpG loci analysed for G-CIMP association. The β-value difference in DNA methylation between G-CIMP+ and G-CIMP− tumours is plotted along the x axis. The P value between G-CIMP+ and G-CIMP− tumours is plotted on the y axis (−log10 scale). Redindicatessignificantly different probes. c, Concordance between hypermethylated sites in mutant IDH1-expressing astrocytes and G-CIMP+ LGGs. GSEA shows significant enrichment between 730 hypermethylated unique CpG sites identified in IDH1 mutant astrocytes (ANOVA between passage 2 and 40) and those present in G-CIMP+ gliomas. GSEA correlation shown in colour scale. ES, enrichment score; FDR, false discovery rate; FEWR, familywise error rate; NES, normalized enrichment score; NOM, nominal P value. d, Differential methylation in IDH mutant astrocytes correctly classifies G-CIMP in the human LGGs. Two-dimensional-unsupervised hierarchical clustering of 81 human gliomas with top variant probes (n = 10,000) from mutant IDH1 astrocytes. Tumours are shown on the y axis, probes along the x axis. Methylation (β value) for each probe is represented with the colour scale. G-CIMP classification as determined by the astrocyte-derived data is denoted by the colour bars at the left. e, Kaplan–Meier survival curve of 115 patients with grade II or grade III gliomas in the Rembrandt Database grouped by CIMP status. P value calculated by log rank.

  4. Functional implications of IDH1-mutation-induced alterations in the glioma epigenome.
    Figure 4: Functional implications of IDH1-mutation-induced alterations in the glioma epigenome.

    a, Concordance of transcriptional programs regulated by mutant IDH1 in astrocytes and G-CIMP in LGGs. P value for significance is shown along the x axis. Yellow lines indicate threshold of significance (P = 0.05). b, Mutant IDH1 results in the expression of markers of self-renewal and stem cell identity. Left, mutant IDH1 results in expression of nestin. Pindicatespassage number. Right, expression of mutant IDH1 promotes the adoption of a neurosphere phenotype. Astrocytes (passage 15) that express IDH R132H or IDH1 wild type were used in the neurosphere assay. Error bars indicate 1 s.d. **P<0.01 (t-test). c, Alterations in histone marks in IDH1-mutant-expressing human astrocytes. Left, western blot results are shown using the indicated antibodies. Astrocytes are from passage 27. Right, ChIP of the indicated histone marks for representative hypermethylated genes. Error bars indicate 1 s.d. *P<0.05. d, Mutant IDH1 inhibits the production of 5hmC in human astrocytes. Left, mutant IDH inhibits TET2-dependent 5hmC production in astrocytes. Parental astrocytes were infected with lentivirus directing the expression of TET2 catalytic domain and green fluorescent protein (GFP) ± mutant IDH1. FACS analyses are shown for 5hmC. Right, astrocytes expressing IDH R132H (passage 10) have less 5hmC than astrocytes that do not express the IDH mutant.

Accession codes

Primary accessions

Gene Expression Omnibus

Change history

Corrected online 27 February 2012
The original supplementary figures PDF was corrupted and has been replaced.

References

  1. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510522 (2010)
  2. Fang, F. et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med. 3, 75ra25 (2011)
  3. Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 86818686 (1999)
  4. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765773 (2009)
  5. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 18071812 (2008)
  6. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268274 (2006)
  7. Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 10581066 (2009)
  8. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739744 (2009)
  9. Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553567 (2010)
  10. Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225234 (2010)
  11. Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683692 (2007)
  12. Ohm, J. E. et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature Genet. 39, 237242 (2007)
  13. Cheng, Y. W. et al. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin. Cancer Res. 14, 60056013 (2008)
  14. Sonoda, Y. et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 61, 49564960 (2001)
  15. Vivanco, I. et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11, 555569 (2007)
  16. Sonoda, Y. et al. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 61, 66746678 (2001)
  17. Pieper, R. O. Defined human cellular systems in the study of glioma development. Front. Biosci. 8, s19s27 (2003)
  18. Bibikova, M. et al. High density DNA methylation array with single CpG site resolution. Genomics 98, 288295 (2011)
  19. Sandoval, J. et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6, 692702 (2011)
  20. Mutskov, V. & Felsenfeld, G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J. 23, 138149 (2004)
  21. Bracken, A. P. et al. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20, 11231136 (2006)
  22. Furnari, F. B. et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21, 26832710 (2007)
  23. Docherty, S. J. et al. Bisulfite-based epityping on pooled genomic DNA provides an accurate estimate of average group DNA methylation. Epigenetics Chromatin 2, 3 (2009)
  24. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 9971003 (2005)
  25. Solomon, D. A. et al. Identification of p18INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res. 68, 25642569 (2008)
  26. Etcheverry, A. et al. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics 11, 701 (2010)
  27. The Cancer Genome Atlas Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 10611068 (2008)
  28. Lendahl, U., Zimmerman, L. B. & McKay, R. D. CNS stem cells express a new class of intermediate filament protein. Cell 60, 585595 (1990)
  29. Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 1730 (2011)
  30. He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 13031307 (2011)
  31. Reich, M. et al. GenePattern 2.0. Nature Genet. 38, 500501 (2006)
  32. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98110 (2010)
  33. Thomas, P. D. et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 13, 21292141 (2003)
  34. Rhodes, D. R. et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9, 443454 (2007)
  35. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 1554515550 (2005)
  36. Vlassenbroeck, I. et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J. Mol. Diagn. 10, 332337 (2008)
  37. Gordon, D., Abajian, C. & Green, P. Consed: a graphical tool for sequence finishing. Genome Res. 8, 195202 (1998)
  38. Nickerson, D. A., Tobe, V. O. & Taylor, S. L. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res. 25, 27452751 (1997)
  39. Chen, K. et al. PolyScan: an automatic indel and SNP detection approach to the analysis of human resequencing data. Genome Res. 17, 659666 (2007)
  40. Major, J. E. Genomic mutation consequence calculator. Bioinformatics 23, 30913092 (2007)
  41. Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 70117021 (2004)
  42. De Filippis, L. et al. A novel, immortal, and multipotent human neural stem cell line generating functional neurons and oligodendrocytes. Stem Cells 25, 23122321 (2007)

Download references

Author information

  1. These authors contributed equally to this work.

    • Sevin Turcan,
    • Daniel Rohle &
    • Anuj Goenka

Affiliations

  1. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA

    • Sevin Turcan,
    • Daniel Rohle,
    • Anuj Goenka,
    • Logan A. Walsh,
    • Fang Fang,
    • Emrullah Yilmaz,
    • Carl Campos,
    • Armida W. M. Fabius,
    • Andrew Kaufman,
    • Olga Guryanova,
    • Ross Levine,
    • Adriana Heguy,
    • Luc G. T. Morris,
    • Jason T. Huse,
    • Ingo K. Mellinghoff &
    • Timothy A. Chan
  2. Weill Cornell College of Medicine, New York, New York 10065, USA

    • Daniel Rohle,
    • Ingo K. Mellinghoff &
    • Timothy A. Chan
  3. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA

    • Anuj Goenka &
    • Timothy A. Chan
  4. Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA

    • Chao Lu,
    • Patrick S. Ward &
    • Craig B. Thompson
  5. Department of Cancer Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA

    • Chao Lu &
    • Patrick S. Ward
  6. Genomics Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA

    • Agnes Viale
  7. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA

    • Luc G. T. Morris
  8. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA

    • Jason T. Huse
  9. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA

    • Ingo K. Mellinghoff
  10. Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA

    • Ingo K. Mellinghoff &
    • Timothy A. Chan

Contributions

T.A.C., S.T., A.G. and I.K.M. designed the experiments. S.T., A.G., F.F., D.R., A.H., L.A.W., C.C., E.Y., C.L., P.S.W., A.V., J.T.H., A.W.M.F. and L.G.T.M. performed the experiments. S.T., J.T.H., A.G., F.F., A.K., A.H., E.Y., A.V., P.S.W., C.B.T., T.A.C. and I.K.M. analysed the data. D.R., O.G., R.L. and I.K.M. contributed new reagents. T.A.C., S.T., I.K.M. and A.G. wrote the paper.

Competing financial interests

C.B.T. is a consultant of Agios Pharmaceuticals and has a financial interest in Agios.

Corresponding authors

Correspondence to:

Data sets have been deposited in the Gene Expression Omnibus under accession number GSE30339.

Author details

Supplementary information

PDF files

  1. Supplementary Figures (3.6M)

    This file contains Supplementary Figures 1-14 with legends. These figures show methylation profiles of parental, IDH1 wild-type and IDH1 mutant astrocytes; validation of differentially methylated regions using EpiTYPER; association of CIMP identified from lower grade gliomas with various clinical covariates; predictive power of the 17-gene signature on the MSKCC cohort and the Rembrandt validation dataset; promotion of a neurosphere phenotype in human astrocytes upon mutant IDH1 expression. The original file posted on line was corrupted and was replaced on 27 February 2012.

Zip files

  1. Supplementary Tables 1-17 (7.9M)

    Table 1 shows the differentially methylated genes at passage 40 in IDH1 R132H expressing human astrocytes.
    Table 2 shows the differentially expressed genes at passage 40 in IDH1 R132H expressing human astrocytes.
    Table 3 shows the enrichment of PANTHER pathways and biological processes in differentially expressed genes at passage 40 in mutant IDH1 expressing human astrocytes.
    Table 4 includes the enriched literature defined Oncomine concepts in mutant IDH1 expressing human astrocytes.
    Table 5 includes the patient characteristics for the MSKCC Cohort used for methylation and expression screens (MS Excel spreadsheet; 49 KB).
    Table 6 shows the differentially methylated genes between CIMP groups in MSKCC cohort of lower grade glioma samples (MS Excel spreadsheet; 9.9 MB).
    Table 7 shows the enriched gene sets and PRC2 targets as identified by GSEA in CIMP+ tumors.
    Table 8 shows the differentially expressed genes in CIMP tumors.
    Table 9 shows the PANTHER ontology terms enriched in the differentially expressed genes in CIMP tumors.
    Table 10 shows the multivariate analysis of predictors of CIMP in MSKCC Cohort.
    Table 11 shows the multivariate analysis of survival in lower grade gliomas (MS Word document 156 KB).
    Table 12 shows the hypermethylated and downregulated genes in CIMP positive tumors.
    Table 13 shows the hypermethylated probes used for GSEA.
    Table 14 shows the differentially methylated probes from IDH1 expressing human astrocytes used to classify CIMP tumors from MSKCC cohort.
    Table 15 shows the 17 gene signature derived from clinical and cell line data used to classify TCGA samples.
    Table 16 shows the multivariate analysis of predictors of survival in Rembrandt validation data set.
    Table 17 shows the EpiTYPER primers used for validation of methylated genes in IDH1 expressing astrocytes and LGG tumors.

Additional data